2021.02.18

Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test. Kondo T, et al, Int. J. Hematol.110(4): 482-489, 2019

2021.02.18

Pre-treatment evaluation of FRET-based drug sensitivity test for patients with CML treated with dasatinib. Kondo T, et al, Cancer Sci. 109(7): 2256-2265, 2018

2021.02.18

Improved FRET biosensor for the measurement of BCR-ABL activity in chronic myeloid leukemia cells. Horiguchi, M. et al, Cell Struct. Funct. 42(1): 15-26, 2017

2021.02.18

A novel FRET-based biosensor for the measurement of BCR–ABL activity and its response to drugs in living cells. Mizutani, T. et al, Clin. Cancer Res. 16(15): 3964-3975, 2010